Simcere, a Nanjing pharma, in-licensed greater China rights to a treatment for gout from JW Pharmaceutical (KRX: 001060) of Korea. URC-102, a selective inhibitor of uric acid transporter (URAT-1), is currently in a South Korean Phase IIb clinical trial. According to the companies, current treatments for gout are prone to adverse effects and not always effective. Simcere will be responsible for the clinical research, registration and commercialization of URC-102 in China, Hong Kong and Macau. JWP will receive an upfront payment, milestones and China royalties, though specific details were not disclosed.
Source: China Biotoday
